[1] Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr, 2016, 5:415-421.
[2] Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet, 2014, 384:2053-2063.
[3] Yasunaka T, Takaki A, Yagi T, et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int, 2011, 5:918-926.
[4] Yang HC, Kao JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect, 2014, 3:e64.
[5] Datta S. Compartmentalization of hepatitis B virus: Looking beyond the liver. World J Hepatol, 2015, 7:2241-2244.
[6] Trigo C, do Brasil PE, Costa MJ, et al. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment. J Viral Hepat, 2016, 23:1027-1035.
[7] Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol, 2012, 56:1189-1197.
[8] Veerappan A, VanWagner LB, Mathew JM, et al. Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin. Hum Immunol, 2016, 77:367-374.
[9] Shin E, Kim JH, Yu E. Histopathological causes of late liver allograft dysfunction: analysis at a single institution. Korean J Pathol, 2013, 47:21-27.
[10] Matsui T, Kang JH, Nojima M, et al. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol, 2013, 85:1900-1906.
[11] Frank MG, Watkins LR, Maier SF. The permissive role of glucocorticoids in neuroinflammatory priming: mechanisms and insights. Curr Opin Endocrinol Diabetes Obes, 2015, 22:300-305.
[12] Maiwall R, Kumar M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol, 2016, 4:54-65.
[13] Xie SB, Zhu JY, Ying Z, et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation, 2010, 90:786-790.
[14] Al-Hamoudi W, Elsiesy H, Bendahmash A, et al. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol, 2015, 21:8140-8147.
[15] Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl, 2005, 11:402-409.
[16] Wu TJ, Chen TC, Wang F, et al. Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One, 2012, 7:e32189.
[17] Na GH, Kim DG, Han JH, et al. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation. J Gastroenterol Hepatol, 2014, 29:151-156.
[18] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版). 肝脏, 2015, 10:348-357.
[19] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63:261-283.
[20] Shen S, Jiang L, Xiao GQ, et al. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. World J Gastroenterol, 2015, 21:584-592.
[21] De Simone P, Romagnoli R, Tandoi F, et al. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study. Transplantation, 2016, 100:1507-1512.
[22] Zheng JN, Zou TT, Zou H, et al. Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther, 2016, 14:979-987.
[23] Lee JG, Lee J, Lee JJ, et al. Adefovir- or Lamivudine-Induced Renal Tubular Dysfunction after Liver Transplantation. Medicine (Baltimore), 2015, 94:e1569.
[24] Yoshizawa A, Yamashiki N, Ueda Y, et al. Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res, 2016, 46:541-551.
[25] Usui M, Sugimoto K, Kato H, et al. Discontinuation of Hepatitis B Immunoglobulin by Long-term Hepatitis B Vaccine Inoculation in Preventing Hepatitis B Recurrence After Liver Transplantation. Transplant Proc, 2016, 48:1179-1183.
[26] Geng L, Lin BY, Shen T, et al. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative. Hepatobiliary Pancreat Dis Int, 2016, 15:316-318.
[27] Lenci I, Baiocchi L, Tariciotti L, et al. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression. Liver Transpl, 2016, 22:1205-1213.
[28] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife, 2012, 1:e00049.
[29] Wei Q, Xu X, Wang C, et al. Efficacy and Safety of a Steroid-Free Immunosuppressive Regimen after Liver Transplantation for Hepatocellular Carcinoma. Gut Liver, 2016, 10:604-610. |
